Skip to main content
editorial
. 2022 Feb 26;8:84. doi: 10.1038/s41420-022-00881-1

Fig. 3. MYSM1 increases cellular apoptosis, ROS production, and decreases cell viability upon cisplatin treatment.

Fig. 3

MDA-MB-231 and Hs578T cells with MYSM1 overexpression and knockdown and their corresponding negative control cells were treated with or without cisplatin (5 µg/mL) for 48 h. A Flow cytometry was performed to detect PE/Annexin V staining and evaluate apoptosis. B The cleaved PARP, full-length PARP, cleaved caspase-7, procaspase-7, cleaved caspase-9, and procaspase-9 were detected by western blot. C Flow cytometry was performed to detect DHE staining and evaluate ROS production. D CCK8 assay was performed to measure cell viabilities. All data in the graph bars represent means ± SD. *P < 0.05 and **P < 0.01.